Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Dofetilide is a new antiarrhythmic agent recently approved for the conversion of and maintenance of sinus rhythm in patients with atrial fibrillation (AF) and atrial flutter (AFI). Dofetilide is a selective class III antiarrhythmic drug which works by selectively blocking the rapid component of the delayed rectifier outward potassium current (Ikr). Dofetilide has been shown to prolong the effective refractory period which is accompanied by a dose-dependent prolongation of the QT and QTc intervals, with parallel increases in ventricular refractoriness. Approximately 80% of dofetilide is excreted in the urine which requires dose adjustments in renal insufficiency. The elimination half-life is approximately 10 h in patients with normal renal function. The therapeutic blood level range of dofetilide is presently unknown and monitoring of dofetilide blood levels is not available at this time. Clinical trials have shown dofetilide to be superior to flecainide in converting AFI patients to normal sinus rhythm (NSR) (70% vs. 9%; p

Original languageEnglish
Pages (from-to)759-771
Number of pages13
JournalDrugs of Today
Volume36
Issue number11
DOIs
StatePublished - 2000

Fingerprint

Atrial Flutter
Atrial Fibrillation
Maintenance
Flecainide
Anti-Arrhythmia Agents
dofetilide
Renal Insufficiency
Half-Life
Potassium
Clinical Trials
Urine
Kidney

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

@article{141fcb5ab222427fa09e7c945a9839bb,
title = "Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter",
abstract = "Dofetilide is a new antiarrhythmic agent recently approved for the conversion of and maintenance of sinus rhythm in patients with atrial fibrillation (AF) and atrial flutter (AFI). Dofetilide is a selective class III antiarrhythmic drug which works by selectively blocking the rapid component of the delayed rectifier outward potassium current (Ikr). Dofetilide has been shown to prolong the effective refractory period which is accompanied by a dose-dependent prolongation of the QT and QTc intervals, with parallel increases in ventricular refractoriness. Approximately 80{\%} of dofetilide is excreted in the urine which requires dose adjustments in renal insufficiency. The elimination half-life is approximately 10 h in patients with normal renal function. The therapeutic blood level range of dofetilide is presently unknown and monitoring of dofetilide blood levels is not available at this time. Clinical trials have shown dofetilide to be superior to flecainide in converting AFI patients to normal sinus rhythm (NSR) (70{\%} vs. 9{\%}; p",
author = "Lenz, {Thomas L.} and Hilleman, {Daniel E.}",
year = "2000",
doi = "10.1358/dot.2000.36.11.601530",
language = "English",
volume = "36",
pages = "759--771",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "11",

}

TY - JOUR

T1 - Dofetilide

T2 - A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter

AU - Lenz, Thomas L.

AU - Hilleman, Daniel E.

PY - 2000

Y1 - 2000

N2 - Dofetilide is a new antiarrhythmic agent recently approved for the conversion of and maintenance of sinus rhythm in patients with atrial fibrillation (AF) and atrial flutter (AFI). Dofetilide is a selective class III antiarrhythmic drug which works by selectively blocking the rapid component of the delayed rectifier outward potassium current (Ikr). Dofetilide has been shown to prolong the effective refractory period which is accompanied by a dose-dependent prolongation of the QT and QTc intervals, with parallel increases in ventricular refractoriness. Approximately 80% of dofetilide is excreted in the urine which requires dose adjustments in renal insufficiency. The elimination half-life is approximately 10 h in patients with normal renal function. The therapeutic blood level range of dofetilide is presently unknown and monitoring of dofetilide blood levels is not available at this time. Clinical trials have shown dofetilide to be superior to flecainide in converting AFI patients to normal sinus rhythm (NSR) (70% vs. 9%; p

AB - Dofetilide is a new antiarrhythmic agent recently approved for the conversion of and maintenance of sinus rhythm in patients with atrial fibrillation (AF) and atrial flutter (AFI). Dofetilide is a selective class III antiarrhythmic drug which works by selectively blocking the rapid component of the delayed rectifier outward potassium current (Ikr). Dofetilide has been shown to prolong the effective refractory period which is accompanied by a dose-dependent prolongation of the QT and QTc intervals, with parallel increases in ventricular refractoriness. Approximately 80% of dofetilide is excreted in the urine which requires dose adjustments in renal insufficiency. The elimination half-life is approximately 10 h in patients with normal renal function. The therapeutic blood level range of dofetilide is presently unknown and monitoring of dofetilide blood levels is not available at this time. Clinical trials have shown dofetilide to be superior to flecainide in converting AFI patients to normal sinus rhythm (NSR) (70% vs. 9%; p

UR - http://www.scopus.com/inward/record.url?scp=0034533650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034533650&partnerID=8YFLogxK

U2 - 10.1358/dot.2000.36.11.601530

DO - 10.1358/dot.2000.36.11.601530

M3 - Review article

C2 - 12845335

AN - SCOPUS:0034533650

VL - 36

SP - 759

EP - 771

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 11

ER -